Accessibility Menu

Is AstraZeneca's Dividend Safe?

AstraZeneca faces a stiff patent calendar that could make it a less attractive dividend play than other drugmakers like Pfizer and Bristol Myers.

By Todd Campbell Jun 30, 2014 at 5:00PM EST

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.